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ABSTRACT 1 
 2 
The feline homologue of CD134 (fCD134) is the primary binding receptor for feline 3 
immunodeficiency virus (FIV), targeting the virus preferentially to activated CD4+ 4 
helper T cells.  However, strains of FIV differ in their utilisation of CD134; the 5 
prototypic strain PPR, requires a minimal determinant in CRD1 of fCD134 to confer 6 
near optimal receptor function while strains such as GL8 require additional 7 
determinants in the CD134 CRD2. We map this determinant to a loop in CRD2  8 
governing the interaction between the receptor and its ligand; substitution of amino 9 
acids S78N,S79Y,K80E restored full viral receptor activity to the CDR2 of human 10 
CD134 in the context of feline CD134 with tyrosine-79 appearing to be the critical 11 
residue for restoration of receptor function.  12 
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      The initial event in the process of viral entry into a target cell is the interaction 1 
between the virus and its cellular receptor and the specificity of this interaction  2 
determines both the cell tropism and the pathogenicity of the virus.  The primary 3 
receptor for FIV is CD134 (OX40)13, a member of the tumour necrosis factor 4 
receptor/nerve growth factor receptor  (TNFR/NGFR) family of molecules.  CD134 5 
expression is greatest on activated CD4+ T-helper cells7 thus infection results in a 6 
progressive depletion of T-helper cells an acquired immune deficiency syndrome 7 
(AIDS)-like illness.  Primary isolates of FIV use CD134 as the binding receptor in 8 
conjunction with the chemokine receptor CXCR4 as a co-factor for infection11,13,15. 9 
FIV binds specifically to CD134-expressing cells13, the FIV Env interacts directly 10 
with CD1344 and pre-treatment of virus with sCD134 facilitates infection of CD134-11 
ve / CXCR4+ve cells3.  12 
 The binding site for the PPR strain of FIV has been mapped to the first 13 
cysteine-rich domain (CRD1)3; human CD134 is not a functional receptor for FIV13 14 
and substitution of CRD1 of human CD134 with that of feline CD134 renders the 15 
molecule functional as a receptor for the PPR strain of FIV. However expression of 16 
feline CD134 CRD1 in the context of human CD134 is insufficient to confer receptor 17 
function on many primary strains of FIV, additional determinants in CRD2 of feline 18 
CD134 being required to restore function16, indicating differential utilization of 19 
CD134 by diverse strains of FIV16. In order to map the determinants in CDR2, we 20 
compared the amino acid sequences of the CRD2s of feline and human CD134 21 
(previously we identified the fragment spanning amino acids 65 to 82 as containing 22 
the critical determinant(s)16) and identified amino acid sequence differences (Fig. 1b). 23 
Next, using the human CRD2 containing chimaera FFHH as our template, we 24 
proceeded to mutate the remaining amino acids in CRD2 from the human sequence to 25 
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the feline. The following mutations were introduced: R66L, P67Q (RP>LQ); G69A, 1 
P70S (GP>AS); D75E,V76A (DV>EA), S78N, K80E (SK>NE), and S78N, S79Y, 2 
K80E (SSK>NYE).  The nucleic acid sequence of each mutant was confirmed; the 3 
constructs were then cloned into the retroviral pDONAI and packaged into MLV 4 
pseudotypes as previous16 and then used to transduce HeLa cells. Stable transductants 5 
were selected in G418 and surface expression of the chimaeric receptors confirmed by 6 
flow cytometry using the BerACT35 monoclonal antibody.  Flow cytometric analysis 7 
confirmed that following G418 selection, the constructs were expressed at comparable 8 
levels at the cell surface (not shown).  9 
The stable cell lines were then seeded into 96-well plates and infected with 10 
HIV(FIV) pseudotypes bearing FIV Envs identified previously as displaying a marked 11 
preference for chimaera FHFH (amino acids 65 to 82 feline in origin) over chimaera 12 
FFHH (amino acids 65 to 82 human in origin); Envs GL8, CPG41 and 0827, or 13 
displaying no or little preference between FHFH and FFHH; Envs 1419, B2542 and 14 
PPR16.  Each of the viral pseudotypes infected parent feline CD134 (FFF)-expressing 15 
cells and the FHFH chimaera-expressing cells with similar efficiency while human 16 
CD134 (HHH)-expressing cells did not differ significantly from control HeLa (CON) 17 
transduced with vector only. Introduction of the R66L, P67Q, G69A, P70S and D75E, 18 
V76A substitutions into the FFHH chimaera did not render the molecule a functional 19 
receptor for GL8, CPG41 and 0827 Env-bearing pseudotypes. S78N, K80E restored 20 
partial function for CPG41 and 0827 Envs while S78N, S79Y, K80E restored full 21 
viral entry receptor function to FFHH for infection with GL8, CPG41 and 0827-Env 22 
bearing pseudotypes. The data suggest that the NYE (Asn78-Tyr79-Glu80) motif in 23 
feline CD134 CRD2 is a critical determinant of receptor function for viruses such as 24 
GL8, CPG41 and 0827 and of these residues, Y79 would appear to be the most 25 
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important. Although the 1419 and B2542 strains showed only weak selectivity for 1 
usage of FHFH over FFHH (<10-fold), the S78N, S79Y, K80E mutation restored full 2 
functionality. In contrast, the PPR strain was at the other extreme from the GL8, 3 
CPG41 and 0827 strains, utilising all chimaeras with similar efficiency. 4 
These findings may indicate that the PPR/CD134 interaction is more relaxed 5 
than the interactions with the GL8, CPG41 and 0827 strains. This may be the result of 6 
either a higher tolerance of the PPR Env for amino acid changes within CRD2 or that 7 
in contrast to GL8, CPG41 and 0827, PPR Env binding to CD134 does not involve 8 
CRD2. Consistent with this hypothesis, the binding site for FIV PPR Env has been 9 
mapped to CRD1 of feline CD134 in the region encompassing residues D60 and 10 
D623. If the structural predictions for feline CD1343,16 prove to be accurate, then the 11 
determinant identified in this study lies in CRD2 on the opposite face of the molecule 12 
from the Env binding site (Figure 2a).  Tyr79 sits at the crown of a loop defined 13 
previously as the “A1 module” of an A1B2 cysteine-rich domain2 (CRD2).  The 14 
crystal structures of the TNF/TNFR1  and  Apo2L/DR56 complexes place this loop at 15 
the ligand-receptor interface (Fig. 2b).  Comparison of the structural predictions for 16 
feline and human CD134 illustrate that feline CD134 would present a bulky tyrosine 17 
residue (Tyr79) at the ligand binding face of the receptor and that this would be 18 
flanked by a negatively-charged glutamate residue (E80). In contrast, human CD134 19 
would have a smaller serine residue (Ser79) flanked by a positively-charged lysine 20 
(Lys80). We have constructed the following models to account for the effect that 21 
substitution of residues 78NYE80 in feline CD134 with 78SSK80 has on the function 22 
of feline CD134 as a viral receptor:  23 
   i. Allosteric effect. An allosteric effect on the binding domain in CRD1, disrupting 24 
recognition of the domain by the GL8, CPG41 and 0827 Envs.  Previous studies on 25 
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the interaction between herpes simplex virus-1 (HSV-1) gD and its receptor HveA 1 
(herpes simplex virus entry mediator A) revealed that binding of the HveA ligands 2 
LT-α (lymphotoxin-A) or  LIGHT to HveA perturbs its function as a receptor for 3 
HSV-1. Conversely, binding of HSV-1 gD to HveA inhibits the interaction between 4 
HveA and LIGHT9.  As HSV-1 gD and LT-α/LIGHT bind to distinct sites on HveA12, 5 
the data indicated that ligand binding to HveA altered the conformation of the 6 
receptor, perturbing its function. By analogy with HveA, the 78NYE80 region in 7 
feline CD134 may be required for maintenance of the Env-binding domain (in CRD1) 8 
and the NYE>SSK substitution alters the conformation of the virus binding domain 9 
sufficiently to ablate recognition by the GL8, CPG41 and 0827 Envs but not PPR 10 
which in turn must recognise a minimal (non-conformation-dependent) determinant.  11 
Accordingly, soluble CRD1 of CD134 does not activate FIV Env for a subsequent 12 
interaction with CXCR4 while a soluble form of the entire extracellular domain of 13 
CD134 facilitates the interaction efficiently5. 14 
    ii. Perturbation of the CD134/CD134L interaction.  Residues 78NYE80 in feline 15 
CD134 may be critical for the interaction between CD134 and CD134L, the A1 16 
module of CRD22 having been shown previously to lie at the receptor-ligand interface 17 
for  TNF/TNFR1  and  Apo2L/DR56.  Alignment of the amino acid sequences of 18 
feline and human CD134 with TNFR1 and DR5 (Fig. 2c) using the Clustal algorithm 19 
places 78NYE80 in same location as the residues of TNFR1 and DR5 CRD2s that are 20 
buried in the receptor-ligand interface (Fig 2c.).  Thus it is likely that residues 21 
78NYE80 are involved in the CD134/CD134L interaction and the NYE>SSK 22 
substitution may disrupt this interaction. In the absence of soluble feline CD134L, we 23 
assessed the binding of soluble human CD134L (shCD134L) to MCC cells expressing 24 
FFHH and FHFH chimaeras (Fig. 2d.).  FFHH bound shCD134L efficiently (63.0% 25 
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positive at 10ng/ml, 97.6% at 100ng/ml), consistent with this chimaera containing the 1 
entire CRD2 of human CD134 and CRD2 governing ligand binding. FHFH bound 2 
shCD134L less efficiently (60.1% at 100ng/ml) consistent with amino acids 65 to 82 3 
of feline CD134 in CRD2 disrupting ligand binding. Binding of shCD134L to 4 
fCD134-expressing MCC cells did not differ significantly from binding to control 5 
MCC cells (18.6% and 15.1% respectively at 100ng/ml). Thus, mutations in the A1 6 
loop of CRD2 disrupt binding of shCD134L to the CRD2 of hCD134. Accordingly, it 7 
is possible that the NYE>SSK substitution disrupts the receptor-ligand interaction and 8 
in doing so, prevents recognition of a multimeric form of the receptor by the GL8, 9 
CPG41 and 0827 Envs. Further dissection of the role of the receptor-ligand 10 
interaction in viral receptor function will require the cloning and expression of 11 
functional feline CD134L. However, it is notable that cell lines known to be highly 12 
susceptible to FIV express not only CXCR4 and CD134, but also CD134L (Table 1). 13 
   Given that the interaction between the GL8, CPG41 and 0827 Envs would 14 
appear to be complex and involve regions of the CRD2 of CD134 predicted to lie at 15 
the receptor-ligand interface, our studies raise the possibility that infection by such 16 
viruses may well be modulated (inhibited or enhanced) by the natural ligand for feline 17 
CD134 (CD134L or OX40 ligand).   18 
The biological significance of differences in the affinity of virus-receptor 19 
interaction has been revealed by studies on the adaptation of HIV for growth in cell 20 
culture; primary strains displaying differential requirements for levels of CD4 and 21 
CXCR414. These findings are mirrored by analyses of the molecular determinants of 22 
viral growth in microglia, where microglia-tropic strains utilise CD4 more efficiently 23 
by way of a higher affinity Env-CD4 interaction and increased exposure of the 24 
chemokine receptor binding site8. Further, a high affinity interaction between the 25 
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prCBL23 Env and CD4 may mediate Lv2 restriction10. Revealing the biological 1 
significance of the differential utilization of CD134 by FIVs may inform the design of 2 
novel strategies for vaccination and therapy and further strengthen the comparative 3 
value of FIV infection of the domestic cat as a non-primate model for HIV and AIDS. 4 
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Figure 1. (a.) Schematic representation of the FFHH and FHFH CD134 chimaeras16 1 
highlighting FIV PPR binding site3, tyrosine-79 (Y79) and serine-79 (S79). (b.) 2 
Amino acid sequence comparison of the region spanning CRD1 and CRD2 of CD134.  3 
Divergent amino acids in region 65 to 85 targeted for mutagenesis are shaded. (c.) 4 
HeLa cells transduced with CD134 mutants and stably selected in G418 were infected 5 
with HIV (FIV) luciferase pseudotypes bearing GL8, CPG41, 0827, 1419, B2542 and 6 
PPR Envs. Luciferase activity (CPM/ml) was quantified 72 hrs post-infection, each 7 
bar represents mean +/- SE, n=3. 8 
 9 
Figure 2. (a.) Predicted 3D-structures of feline and human CD134 showing the 10 
locations of the FIV-PPR SU binding site (59GDQD623, “BS”) and the 78NYE80 and 11 
78SSK80 regions of feline and human CD134 respectively. (b.) Location of H66, L67 12 
and R68 (space-filling spheres) on TNFR (c.) Amino acid sequence comparison of the 13 
A1 modules of the CRD2s of feline CD134, human CD134, TNFR1, DR5 (Apo2) and 14 
Fas.   78NYE80 and 78SSK80 are boxed. Residues that bury more than 50% of their 15 
accessible surface area in the TNF/TNFR and Apo2L/DR5 receptor-ligand interface6 16 
are shown in bold. (d.) Flow cytometric analysis of binding of shCD134L to MCC 17 
cells expressing fCD134 or the chimaeras FFHH and FHFH. shCD134L (R&D 18 
systems) was incubated at 4oC for 30 mins. before detection with 0.1μg goat anti-19 
human CD134L (R&D systems) followed by FITC-conjugated rabbit anti-goat IgG 20 
(Sigma). 10,000 events were collected per sample. 21 
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Figure 1.  
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Figure 2. 
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Table 1. Real time PCR measurement of CXCR4, CD134 and CD134L. Measurement 
of CD134, CD134L and CXCR4 gene expression by real time reverse transcription 
(RT) PCR. Total RNA was extracted from MBM and MYA T-lymphoid cell lines, 
reverse transcribed into cDNA using random hexamers, and amplified for feline 
CD134, CD134L and CXCR4 and housekeeping glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) as internal control (Pistello et al., submitted). Primers and 
probes are available by e-mail on request. Relative gene expression is given as the 
difference between the threshold cycle (CT) of the target and the CT of internal control 
(ΔCT). 
 
 
 
Sample description GAPDH CD134 CD134L CXCR4 
 Ct Ct ΔCt Ct ΔCt Ct ΔCt 
MBM 20.14 20.46 -0.32 28.52 -8.38 23.66 -3.52 
MYA-1 18.44 18.27 0.17 23.50 -5.06 22.43 -3.99 
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